Taiyo Report issue

For profit Phase 3
Founded: Takayama Japan (1930)
Status: Acquired by Teva (2011)

Organization Overview

First Clinical Trial
2009
NCT00799890
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TAIYO EUROPE

Active Ingredients

Drugs in Phase 3 Trials (1)

l-epigallocatechin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1